AACR 2022 – Novartis’s late Kras challenge to Amgen
Targeting Shp2 has disappointed, but Novartis shows that it might still make an impression in directly hitting Kras.
AACR 2022 – A weekend of updates yields few winners
The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.
AACR 2022 – Biontech’s cell therapy effort bears fruit at last
But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.
AACR 2022 – Affimed shows that 2021 was no fluke
An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.
ACC 2022 – Bristol's rare hit could justify Myokardia
Mavacamten prevails again, but the big question for Bristol is the commercial opportunity.
